More than 170 residents of South Africa are filing suit against Johnson & Johnson subsidiary DePuy Orthopedics over problems with the company’s all-metal hip implants, according to a story on IOL News.
The story says the South African plaintiffs are suing in a court in England — where the implants in question were manufactured — because they were unable to sue in their home country. They’re seeking millions of dollars over ...
continue reading...
According to a story in the National Law Journal, about 40 lawsuits filed over Bayer’s Mirena intrauterine device have been coordinated in multidistrict litigation, and will be heard by a New York federal judge. Attorneys for the plaintiffs said they expect complaints about Mirena IUDs to generate hundreds – perhaps thousands – more lawsuits in the near future.
The T-shaped flexible plastic devices prevent pregnancy by releasing hormones into the ...
continue reading...
Although Johnson & Johnson’s overall profit fell 10.6 percent to $3.5 billion in the first quarter of 2013, over-the-counter sales through the company’s consumer division are up 14 percent in the United States, according to a story in the Philadelphia Inquirer.
The company is putting more Tylenol and Motrin on stores shelves through its McNeil Consumer Healthcare Unit, located outside Philadelphia. Although McNeil also has plants in Lancaster, Pa., and in ...
continue reading...
Scots newspaper Daily Record recently printed a letter that a woman wrote to Scotland’s health secretary, detailing the health problems she’s endured as a result of getting a vaginal mesh implant. She describes herself as “one of the many, many Scots women whose lives have been devastated by mesh surgery.”
But the devices, implanted to treat urinary incontinence and pelvic organ prolapse, have generated complaints globally about their tendency to erode ...
continue reading...
An investing blog on CNBC.com warns potential investors about health care giant Johnson & Johnson.
The stock is already up more than 22 percent on the year, the blog entry says, and trading at a price/earnings ratio more than twice that of rival Abbott Laboratories. But the entry points out that investors are worried about the company’s prospects for organic growth, especially in light of its reputation still being in “recovery” ...
continue reading...
According to Reuters, Merck’s quarterly sales of diabetes drug Januvia – the company’s biggest product – took a nosedive in quarterly sales, which has investors concerned.
Overall, shares of the company fell 1.6 percent to $46.23 for the quarter. Though the company’s profit beat forecasts for the quarter, the Reuters story attributes that largely to a favorable tax rate.
Januvia has been the subject of some health concerns recently. Studies have linked ...
continue reading...
